S-100A13 Antibody (63-Y): sc-100935

S-100A13 Antibody (63-Y) is a mouse monoclonal IgG2a kappa light chain antibody that detects S-100A13 of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-S-100A13 antibody (63-Y) is available as non-conjugated format. S-100A13, a member of the S-100 protein family, is a 98 amino acid protein characterized by two EF-hand calcium-binding domains, which play a crucial role in calcium signaling within cells. S-100A13 is predominantly expressed in skeletal muscle, heart, kidney, ovary, small intestine, and pancreas, and expression levels can vary significantly in different pathological conditions, highlighting potential as a biomarker for various diseases. S-100A13 translocates in response to elevated intracellular calcium levels induced by Angiotensin II, which is important for understanding cellular responses to stress and inflammation. S-100A13 co-localizes with S-100A1 on human chromosome 1q21, where many S-100 proteins cluster, suggesting potential interactions that may influence cellular functions such as inflammation and tumor cell motility. S-100A13′s ability to enhance neurite outgrowth further underscores significance in neurobiology and regenerative medicine, making S-100A13 (63-Y) antibody a valuable tool for researchers studying these critical processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Contains Mercury: All HRP conjugates (including bundle forms) contain thiomersal, a mercury compound. Do not dispose in trash. Dispose as hazardous chemical waste according to local, state and federal regulations.

Download thiomersal SDS

S-100A13 Antibody (63-Y) References:

1. Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family.  |  Shishibori, T., et al. 1999. Biochem J. 338 (Pt 3): 583-9. PMID: 10051426
2. S100A13 and S100A6 exhibit distinct translocation pathways in endothelial cells.  |  Hsieh, HL., et al. 2002. J Cell Sci. 115: 3149-58. PMID: 12118070
3. Differential expression of S100 proteins in the developing human hippocampus and temporal cortex.  |  Chan, WY., et al. 2003. Microsc Res Tech. 60: 600-13. PMID: 12645008
4. S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells.  |  Hsieh, HL., et al. 2004. Biochem Biophys Res Commun. 316: 949-59. PMID: 15033494
5. Feasibility study on measuring selected proteins in malignant melanoma tissue by SRM quantification.  |  Welinder, C., et al. 2014. J Proteome Res. 13: 1315-26. PMID: 24490776
6. Microvessel density, lymphovascular density, and lymphovascular invasion in primary cutaneous melanoma-correlation with histopathologic prognosticators and BRAF status.  |  Aung, PP., et al. 2015. Hum Pathol. 46: 304-12. PMID: 25537974
7. Autologous chondrocyte implantation-derived synovial fluids display distinct responder and non-responder proteomic profiles.  |  Hulme, CH., et al. 2017. Arthritis Res Ther. 19: 150. PMID: 28666451
8. Identification of Candidate Synovial Fluid Biomarkers for the Prediction of Patient Outcome After Microfracture or Osteotomy.  |  Hulme, CH., et al. 2021. Am J Sports Med. 49: 1512-1523. PMID: 33787363
9. Endometrial proteomic profile of patients with repeated implantation failure.  |  Yang, J., et al. 2023. Front Endocrinol (Lausanne). 14: 1144393. PMID: 37583433
10. Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as Potential New Biomarkers in Patients with Diabetes Mellitus and Pancreatic Adenocarcinoma.  |  Kolokotronis, T., et al. 2024. Cancers (Basel). 16: PMID: 39123454
11. Characterization of the human and mouse cDNAs coding for S100A13, a new member of the S100 protein family.  |  Wicki, R., et al. 1996. Biochem Biophys Res Commun. 227: 594-9. PMID: 8878558
12. S100A13 is involved in the regulation of fibroblast growth factor-1 and p40 synaptotagmin-1 release in vitro.  |  Mouta Carreira, C., et al. 1998. J Biol Chem. 273: 22224-31. PMID: 9712836

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-S-100A13 Antibody (63-Y) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-S-100A13 Antibody (63-Y) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

S-100A13 Antibody (63-Y) Specifications

Alternate Product Name: S100 protein A13 (S100A13)

Product Clone Name: 63-Y

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 1-99

Epitope Target: S-100A13

Epitope Species: human

Product Reactivity/Detection: S-100A13

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 100 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for S-100A13 Antibody (63-Y): N/A